ENTX
Entera Bio Ltd.Company Information
- Company Name
- Entera Bio Ltd.
- CIK
- CIK0001638097
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ENTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- ENTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-09
- Last sale
- —
- Shares purchased (TTM)
- 101,500
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 10,605,686
- Shares outstanding
- 50,451,232
- Ownership
- 21.02%
Earnings Market Reaction
- Filing date
- 2026-08-07
- Price on filing date
- —
- 1-month reaction
- 5.57%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 11 | 4 | 7 | 9 | 11 | 13 | 9 | 7 | 9 | 9 | 11 | 8 | ||||||
| Accounts Receivable Net Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | ||||||
| Restricted Cash Current | - | - | 8 | - | - | - | 0 | - | - | - | - | - | ||||||
| Restricted Cash | 7 | 8 | - | 8 | 8 | 8 | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | ||||||
| Assets Current | 19 | 12 | 15 | 17 | 19 | 21 | 9 | 7 | 10 | 10 | 11 | 8 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Income Tax Assets Net | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deposits Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Defined Benefit Plan Assets For Plan Benefits Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Noncurrent | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Assets | 19 | 13 | 16 | 17 | 20 | 22 | 9 | 8 | 10 | 10 | 12 | 9 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Accrued Liabilities And Other Liabilities | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Noncurrent | - | - | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Other Long Term Debt Noncurrent | 0 | 1 | - | 1 | 1 | 1 | - | - | - | - | - | - | ||||||
| Postemployment Benefits Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Noncurrent | 10 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 12 | 2 | 3 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 2 | ||||||
Stockholders Equity Number Of Shares Par Value And Other Disclosures | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Additional Paid In Capital Common Stock | 143 | 140 | 138 | 138 | 136 | 136 | 122 | 118 | 117 | 115 | 115 | 109 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -136 | -129 | -125 | -122 | -119 | -116 | -114 | -112 | -109 | -106 | -104 | -102 | ||||||
| Stockholders Equity | 7 | 11 | 13 | 15 | 17 | 19 | 8 | 6 | 9 | 9 | 10 | 6 | ||||||
| Liabilities And Stockholders Equity | 19 | 13 | 16 | 17 | 20 | 22 | 9 | 8 | 10 | 10 | 12 | 9 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 140 | 140 | 140 | 140 | 140 | 140 | 140 | 140 | 140 | 140 | 140 | 140 | ||||||
| Common Stock Shares Issued | 49 | 47 | 46 | 46 | 45 | 45 | 39 | 37 | 36 | 36 | 35 | 29 | ||||||
| Shares Outstanding | 49 | 47 | 46 | 46 | 45 | 45 | 39 | 37 | 36 | 36 | 35 | 29 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialEntera Bio Ltd. (ENTX) — SEC Financial Statements & Analysis
Entera Bio Ltd. (ENTX) is a biological products, (no diagnostic substances) company, incorporated in L3. Entera Bio Ltd. trades on Nasdaq as: ENTX. Entera Bio Ltd. (ENTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, Entera Bio Ltd. carries a market cap of $89.30M, a P/E ratio of 5.24x, a P/B ratio of 12.29x, a P/S ratio of 2133.59x, an enterprise value of $70.77M, and an EV/EBITDA multiple of 4.90x. On profitability, it posts a gross margin of 4.04%, an operating margin of 27450.00%, a net margin of 27235.71%, a Return on Equity (ROE) of 138.92%, and a Return on Assets (ROA) of 87.02%. Per share, it reports EPS of $0.34, diluted EPS of $0.34, free cash flow per share of $-0.22, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 60.66% year-over-year, and EPS growth of 49.15% year-over-year. On the balance sheet, it maintains a current ratio of 8.98x, a quick ratio of 8.76x, working capital of $16.79M, a debt-to-equity ratio of 1.68x, a debt ratio of 0.63, free cash flow of $-10.96M (TTM), and net debt of $-18.53M. Figures sourced from SEC EDGAR.
- Market Cap
- $89.30M
- P/E TTM
- 5.24x
- EPS TTM
- $0.34
- P/B TTM
- 12.29x
- ROE TTM
- 138.92%
- ROA TTM
- 87.02%
- Debt To Equity
- 1.68x
- Free Cash Flow TTM
- $-10.96M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Entera Bio Ltd. in?
Entera Bio Ltd. (ENTX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does ENTX trade on?
Entera Bio Ltd. (ENTX) trades on the Nasdaq.
Where is Entera Bio Ltd. incorporated?
Entera Bio Ltd. is incorporated in Israel.
When was Entera Bio Ltd. (ENTX)'s most recent SEC filing?
Entera Bio Ltd. (ENTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07.
What is ENTX's market cap?
Entera Bio Ltd. (ENTX) has a market capitalization of $89.30M as of 2026-06-30.
What is ENTX's P/E ratio?
Entera Bio Ltd. (ENTX)'s trailing twelve month P/E ratio is 5.24x as of 2026-06-30.
What is ENTX's EPS (earnings per share)?
Entera Bio Ltd. (ENTX)'s trailing twelve month EPS is $0.34 as of 2026-06-30.
What is ENTX's ROE (return on equity)?
Entera Bio Ltd. (ENTX)'s trailing twelve month Return on Equity (ROE) is 138.92% as of 2026-06-30.
What is ENTX's ROA (return on assets)?
Entera Bio Ltd. (ENTX)'s trailing twelve month Return on Assets (ROA) is 87.02% as of 2026-06-30.
What is ENTX's EV/EBITDA?
Entera Bio Ltd. (ENTX)'s trailing twelve month EV/EBITDA is 4.90x as of 2026-06-30.